Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylaxis for IOP Rise After Intravitreal Bevacizumab
NCT02140450Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Feb 2012
- Primary completion
- Jan 2014
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of timolol, brimonidine tartrate + sodium hyaluronate, acetazolamide and Bronchitol in ocular hypertension (5 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Change in Intraocular Pressure. Started Feb 2012; status: completed.
02
Drugs
timololbrimonidine tartrate + sodium hyaluronateacetazolamideBronchitol
03
Conditions
ocular hypertension
Beyond the preview
Go deeper on NCT02140450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140450.